Wondering if GE HealthCare Technologies is trading at a bargain, or if the price has already run ahead of what it’s really worth? You’re not alone, and we’re about to take a closer look at what the numbers suggest.
GE HealthCare shares are up an impressive 11.5% in just the past week, with a modest 2.9% rise in the last month. However, they are still down about 2.7% over the past year.
Recent news headlines have highlighted the company’s leadership in medical imaging and ongoing partnerships in digital health. These factors are drawing renewed investor attention. Moves such as expanding its AI-driven diagnostics platform are sparking conversations about future growth and potential shifts in market dynamics for the sector.
When it comes to valuation, GE HealthCare knocks out 5 out of 6 checks according to our value score. See the details for yourself here. We’ll break down the common valuation approaches next. Stay tuned, as at the end we will reveal an even smarter way to decide whether the stock’s price makes sense.
Find out why GE HealthCare Technologies’s -2.7% return over the last year is lagging behind its peers.
A Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting its future cash flows and discounting them back to today’s dollars. This approach allows investors to look beyond short-term volatility and focus on the underlying ability of the business to generate cash over time.
For GE HealthCare Technologies, the latest reported Free Cash Flow stands at $1.43 billion. Analysts expect that figure to nearly double over the next five years, with Simply Wall St extrapolating projections as far as 2035. By 2028, forecasted Free Cash Flow is estimated at $2.84 billion, and by 2035, projections reach over $4 billion. These forecasts highlight meaningful growth potential based on both external analyst estimates and longer-range models.
Taking all this into account, the DCF model pegs GE HealthCare’s estimated fair value at $124.93 per share. At current trading levels, the stock is about 35.5% below this intrinsic valuation, which suggests the shares may be undervalued according to these calculations.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests GE HealthCare Technologies is undervalued by 35.5%. Track this in your watchlist or portfolio, or discover 929 more undervalued stocks based on cash flows.
GEHC Discounted Cash Flow as at Nov 2025
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for GE HealthCare Technologies.
For profitable companies like GE HealthCare Technologies, the Price-to-Earnings (PE) ratio is a particularly insightful valuation metric. The PE ratio tells investors how much they are paying for each dollar of earnings, making it one of the most widely used metrics for assessing whether a stock is fairly priced in relation to its profits.
A “normal” or “fair” PE ratio depends on multiple factors. Companies with higher growth expectations or lower perceived risk often command higher PE ratios, while those facing heightened risks or lower growth tend to trade at lower multiples. This means context is key, so simple peer or industry comparisons have limitations.
Right now, GE HealthCare Technologies trades at a PE of 16.6x. That is considerably below the Medical Equipment industry average of 28.9x and the peer average of 33.6x. To improve on these broad measures, Simply Wall St calculates a proprietary “Fair Ratio,” which is an estimate of what GE HealthCare’s PE should be, factoring in its growth prospects, profit margins, risk profile, industry landscape, and company size. For GE HealthCare, this Fair Ratio comes in at 26.4x, meaning the current PE is well below what would be considered fair based on all these variables combined.
Unlike standard comparisons, the Fair Ratio adjusts for nuances like future earnings growth, risks, and unique operating metrics, giving a more tailored gauge of valuation. Because GE HealthCare’s PE is noticeably lower than its Fair Ratio, this suggests that by this approach, the shares are undervalued.
Result: UNDERVALUED
NasdaqGS:GEHC PE Ratio as at Nov 2025
PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1440 companies where insiders are betting big on explosive growth.
Earlier we mentioned that there is an even better way to understand valuation, so let’s introduce you to Narratives. A Narrative is a simple way of connecting your personal view of GE HealthCare Technologies with the numbers, allowing you to create and share your own story about where the company is heading, and how that story drives your assumptions for future revenue, profit margins, and what the business is actually worth.
Narratives directly link a company’s story to a financial forecast and then to a fair value, helping you see how the numbers follow from the beliefs and catalysts that matter most to you. On Simply Wall St’s Community page, millions of investors can easily build and update Narratives, combining their qualitative perspective, such as excitement about new AI-driven imaging products or concerns about regulatory changes in China, with specific financial forecasts.
This tool helps you cut through the noise. Compare a Narrative’s fair value to the current price, and you will see when other investors think the stock might be undervalued or overvalued, and why. Narratives are automatically updated as new information like news or earnings reports comes in, so your fair value and forecast stay relevant and grounded in reality.
For GE HealthCare Technologies, Narratives reflect diverse outlooks. Some investors project robust order backlogs, margin expansion, and future price targets as high as $106, while more cautious users factor in tariffs and competition, leading to fair values as low as $73.
Do you think there’s more to the story for GE HealthCare Technologies? Head over to our Community to see what others are saying!
NasdaqGS:GEHC Community Fair Values as at Nov 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GEHC.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
